Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Karus Therapeutics Appoints Penelope Ward as CMO

Published: Tuesday, November 12, 2013
Last Updated: Tuesday, November 12, 2013
Bookmark and Share
Dr Ward will drive Company’s HDAC6 and PI3K inhibitor programmes.

Karus Therapeutics has announced that Penelope Ward has joined the Company in the role of Chief Medical Officer.

Her appointment strengthens the Company’s expansion which recently saw the formation of a Scientific Advisory Board, appointment of additional R&D personnel and a move to a world-class biotech hub near Oxford.

Dr Ward, who took up her new position in October, is an experienced pharmaceutical physician with previous senior management roles at Pharmacia and Upjohn (Pfizer), UCB and Roche, and was previously Chief Medical Officer of Novimmune SA.

Her expertise in designing and implementing clinical development strategies will be important for the role at Karus where she will take responsibility for driving the Company’s HDAC6 and PI3K inhibitor programmes through early human efficacy trials in inflammation and cancer.

In addition, Dr Ward brings with her broad capabilities in commercial licensing negotiations, having previously supported deals for novel research targets to full development candidates.

Along with a solid track record in obtaining regulatory approval, Dr Ward is well placed to assist the Company in future strategic decision making.

Commenting on Dr Ward’s appointment, Dr Simon Kerry, Chief Executive of Karus, said: “With the wealth of expertise that Penny brings to the position, we are confident she will be an asset to the team and look forward to working together to further develop and strengthen our proprietary programmes to treat inflammation and cancer.”

Dr Ward, Chief Medical Officer, added: “Karus is at a very exciting stage in its development, being well funded by supportive investors and with a great team. I look forward to working with the Board, management and scientists to progress the Company’s assets and realize the potential of its technology.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Karus Therapeutics Appoints Scientific Advisory Board
Company announces move to new Oxford facilities.
Tuesday, April 09, 2013
Karus Secures Series B Financing from a Syndicate of Leading VC Investors
New investment to support the development of Karus’s innovative PI3K and HDAC6 programmes through early human trials.
Thursday, January 17, 2013
Karus Therapeutics Announces Collaboration with Babraham Institute
Collaboration to explore PI3 kinase inhibitors in the treatment of inflammatory diseases.
Tuesday, December 18, 2012
Karus Commences Preclinical Development of Novel Immune and Inflammation Programmes
The Company aims to initiate clinical trials for both programmes in 2011.
Wednesday, November 03, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos